Company presentation to focus on how IceCure's
industry-leading ProSense® enables non-surgical treatment of benign
and cancerous tumors and upcoming near-term
regulatory and operating catalysts
CAESAREA, Israel, Sept. 4,
2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced that the Company's Chief Executive Officer, Eyal Shamir, will conduct one-on-one meetings
with institutional investors at both the H.C. Wainwright and Lake
Street Capital Markets conferences, while the Company's Chief
Financial Officer and Chief Operating Officer, Ronen Tsimerman, will join the H.C. Wainwright
meetings virtually.
Investors should contact their sales representatives at H.C.
Wainwright and Lake Street Capital Markets or contact
mpolyviou@evcgroup.com to schedule one-on-one meetings with the
Company's management team.
Event: H.C. Wainwright 26th Annual Global
Investment Conference
Date: September 9-11,
2024
Presentation Time: Virtual presentation to start
on-demand on September 9 at
7:00 AM ET
In-Person One-on-One Meetings: Lotte New York Palace
Hotel, New York
Institutional investors who would like to listen to the Company's
presentation, may click on the following link
(www.hcwevents.com/annualconference) to register for the
conference.
Event: Lake Street Capital Markets 8th
Annual Best Ideas Growth Conference
Date: September 12,
2024
In-Person One-on-One Meetings: New York
The Best Ideas Growth Conference is an annual invitation-only
event, featuring dynamic, small-cap companies interacting with top
institutional investors. The format has been designed to give
attendees direct access to senior management via one-on-one &
group meeting formats.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced
liquid-nitrogen-based cryoablation therapy systems for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The Company's flagship ProSense® system
is marketed and sold worldwide for the indications cleared and
approved to date including in the U.S., Europe and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses its
presentation and anticipated meetings with investors at the H.C.
Wainwright and Lake Street Capital Markets Conferences. Historical
results of scientific research and clinical and preclinical trials
do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Important
factors that could cause actual results, developments and business
decisions to differ materially from those anticipated in these
forward-looking statements include, among others: the Company's
planned level of revenues and capital expenditures; the Company's
available cash and its ability to obtain additional funding; the
Company's ability to market and sell its products; legal and
regulatory developments in the United
States and other countries; the Company's ability to
maintain its relationships with suppliers, distributors and other
partners; the Company's ability to maintain or protect the validity
of its patents and other intellectual property; the Company's
ability to expose and educate medical professionals about its
products; political, economic and military instability in the
Middle East, specifically in
Israel; as well as those factors
set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2023 filed with the SEC on
April 3, 2024, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-to-meet-institutional-investors-at-the-hc-wainwright-and-lake-street-capital-markets-conferences-302237748.html
SOURCE IceCure Medical
